Kevin L. Carter

Combination Chemotherapy in Advanced Adrenocortical Carcinoma

08/16/2012

The 5-year survival rate for adrenocortical carcinoma, a rare cancer with a poor prognosis, is <15% among patients with metastatic disease. Mitotane is the only drug approved for the treatment of adrenocortical carcinoma and is used both...

The 5-year survival rate for...

08/16/2012

First Report Managed Care

Conference Insider

The Landscape for Brand and Generic Drugs

11/20/2013

Kevin L. Carter ;

San Antonio—With more patented drugs reaching the patent cliff—the expiration of a patented drug that allows for the production of generics to compete—this will affect therapies and is expected to account for $74 billion in sales between 2013...

San Antonio—With more patented...

11/20/2013

First Report Managed Care

Time to Initiation of DMARDs among Patients with RA

05/24/2012

Kevin L. Carter ;

San Francisco—Rheumatoid arthritis (RA) is a chronic, inflammatory disorder characterized by pain, progressive disability due to inflammation, and joint destruction. Patients with RA often face daunting economic and comorbid burdens. Most...

San Francisco—Rheumatoid...

05/24/2012

First Report Managed Care

News Connection

An Analysis of 13-Valent Vaccines for Infants

12/17/2013

Kevin L. Carter ;

According to the World Health Organization, more than 800,000 children <5 years of age died from pneumococcal disease in 2000, making it the leading vaccine-preventable cause of death worldwide.

According to the World Health...

12/17/2013

First Report Managed Care

Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations

02/14/2013

Kevin L. Carter ;

The treatment of metastatic melanoma has been greatly enhanced by pharmacologic inhibition of the mitogen-activated protein kinase (MAPK) pathway. Trametinib mediates blockade of MAPK kinase (MEK), which is downstream of BRAF in the MAPK...

The treatment of metastatic...

02/14/2013

First Report Managed Care

Department

Infliximab for Treatment-Resistant Depression

04/22/2013

Kevin L. Carter ;

About one third of depressed patients fail to respond to conventional antidepressant medication. It is believed that inflammation is a possible mechanism that contributes to this treatment resistance. A number of inflammatory biomarkers...

About one third of depressed...

04/22/2013

First Report Managed Care

Rapid Whole-Genome Sequencing in a Neonatal MRSA Outbreak

08/16/2012

Kevin L. Carter ;

Although rapid whole-genome sequencing has been successfully used as a research tool with discriminatory power in outbreaks, it is also potentially useful for its possible clinical utility in a diagnostic setting. A compelling target is...

Although rapid whole-genome...

08/16/2012

First Report Managed Care

Conference Insider

Federal and State Legislative Update

05/17/2013

Kevin L. Carter ;

San Diego—The federal budget sequester struggle, the continuing movement toward the implementation of the Patient Protection and Affordable Care Act (ACA), and issues facing Medicare Part D are among the most significant legislative and...

San Diego—The federal budget...

05/17/2013

First Report Managed Care

Comparative Effectiveness Research by States

05/24/2012

Kevin L. Carter ;

San Francisco—Jenny Gaffney, a senior manager with Avalere Health in Washington, said at the AMCP meeting that over the past few years comparative effectiveness research (CER) has been utilized increasingly by states looking to improve the...

San Francisco—Jenny Gaffney, a...

05/24/2012

First Report Managed Care

News Connection

Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis

10/23/2013

Kevin L. Carter ;

Vedolizumab, a humanized monoclonal antibody, selectively blocks gut lymphocyte trafficking without interfering with trafficking to the central nervous system.

Vedolizumab, a humanized...

10/23/2013

First Report Managed Care